Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860981 | 0.90 | MAPK1 (0.48) | MAPK1KMT2AALDH1A1MGLL | |
| SCHEMBL2575973 | 0.83 | CA12 (0.42) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL11595533 | 0.83 | MAPK1 (0.43) | MAPK1KMT2AALDH1A1MGLL | |
| SCHEMBL1696190 | 0.83 | NPC1 (0.47) | PARP1MAPK1NPC1RAB9AESR1 | |
| SCHEMBL13569375 | 0.83 | MAPK1 (0.43) | CA12CA1CA9MAPK1KMT2A | |
| SCHEMBL317700 | 0.83 | PLA2G7 (0.50) | PARP1MAPK1NPC1RAB9AESR1 | |
| SCHEMBL317765 | 0.83 | MAPK1 (0.43) | MAPK1KMT2AALDH1A1MGLL | |
| SCHEMBL1284517 | 0.83 | TSHR (0.48) | PARP1MAPK1RAB9AKDM4EKMT2A | |
| SCHEMBL15305953 | 0.83 | MAPK1 (0.43) | MAPK1RAB9AKMT2AALDH1A1MGLL | |
| SCHEMBL13950373 | 0.83 | MAPK1 (0.43) | MAPK1RAB9AKMT2AALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023061482-A1 | EPHA2 BICYCLIC PEPTIDE LIGAND AND CONJUGATE THEREOF | 海思科医药集团股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20080193377-A1 | Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-08-14 | — | — | US | disclosed |
| EP-1768706-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | University of Maryland, Baltimore (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006012355-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | CA12 135/4885CA1 669/4885CA2 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.